Alivus Life Sciences Limited has announced the allotment of 55,000 equity shares under its Employee Stock Option Scheme 2021. The company's Nomination and Remuneration Committee approved this allotment during its meeting held on January 21, 2026.

Share Allotment Details

The allotted shares have a face value of ₹2.00 each and were issued to eligible employees who exercised their stock options under the Employee Stock Option Scheme 2021. This allotment represents the company's commitment to its employee incentive programs and stock-based compensation structure.

Impact on Share Capital

The allotment has resulted in an increase in the company's paid-up share capital structure:

The allotment increased the total number of outstanding equity shares by 55,000, representing a marginal increase in the company's equity base. The paid-up share capital rose by ₹1,10,000, reflecting the face value of the newly allotted shares.

Regulatory Compliance

Alivus Life Sciences has informed both the BSE Limited and National Stock Exchange of India Limited about this allotment, ensuring compliance with listing requirements and transparency obligations. The company operates under scrip code 543322 and trades under the symbol ALIVUS on the stock exchanges.

Company Background

Alivus Life Sciences Limited, formerly known as Glenmark Life Sciences Limited, maintains its corporate office at Technopolis Knowledge Park in Mumbai and registered office in Solapur. The company continues to utilize employee stock option schemes as part of its talent retention and incentive strategy.

Alivus Life Sciences Limited has announced its quarterly earnings call to discuss the financial performance for Q3 FY2025-26. The pharmaceutical company, formerly known as Glenmark Life Sciences Limited, has scheduled the investor call for Thursday, January 22, 2026.

Earnings Call Schedule

The company has set the earnings call timing and provided comprehensive access details for participants:

Dial-in Information

Alivus Life Sciences has provided multiple access options for domestic and international participants. The universal dial-in numbers for domestic participants are +91 22 6280 1564 and +91 22 7115 8394.

International Access Numbers

The company has arranged toll-free access for participants from various countries:

For participants who prefer toll numbers, the company has provided international toll options including Hong Kong (+852 30186877), Japan (+81 345899421), Singapore (+65 31575746), South Africa (+27 110623033), UK (+44 2034785524), and USA (+1 3233868721).

Regulatory Compliance and Contact Information

The earnings call announcement was filed under Regulation 30 with both BSE (Scrip Code: 543322) and NSE (Scrip Name: ALIVUS). Company Secretary and Compliance Officer Rudalf Corriea signed the notification on January 15, 2026.

For clarifications regarding the earnings call, participants can contact Diwakar Pingle at Diwakar.Pingle@in.ey.com or Runjhun Jain at Runjhun.Jain1@in.ey.com . The company has also provided a phone contact at +91 9820720993 and offers online pre-registration for the call.

Company Details

Alivus Life Sciences operates from its corporate office at Technopolis Knowledge Park, Andheri (E) Mumbai, with its registered office located in Solapur. The company maintains its investor relations through multiple communication channels and continues to provide regular updates to stakeholders about its financial performance and business developments.